39 results on '"Huillard O"'
Search Results
2. Efficacité et facteurs prédictifs de la réponse à l’immunothérapie dans les carcinomes hypophysaires et les tumeurs hypophysaires agressives : une étude française de cohorte
3. Medical students and the response to COVID-19: Educational preparedness and psychological impact of their involvement in communicating with patients’ relatives
4. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
5. 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
6. 465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program
7. 1059P NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
8. 1048P Should I stay or should I go: Optimal duration for antiPD(L)1 therapy
9. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
10. NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
11. Évaluation pluridisciplinaire préopératoire systématique en chirurgie cancérologique urologique gériatrique : faisabilité et résultats
12. Evaluation of sarcopenia in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A study from the Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology
13. Pharmacokinetic/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients
14. OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial.
15. Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium
16. Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: A retrospective monocentric cohort study
17. La sarcopénie est associée à un pronostic péjoratif pour les tumeurs de vessie infiltrant le muscle traitées par cystectomie totale
18. La sarcopénie est associée à un pronostic péjoratif pour les tumeurs de la voie excrétrice urinaire supérieure traitées par néphrourétérectomie totale
19. Réponse pathologique finale après chimiothérapie néoadjuvante et cystectomie totale : le stade ypT0 associé à une meilleure survie comparé au stade ypTa-pTis-pT1
20. Traitement par lenvatinib des cancers thyroïdiens réfractaires à l’iode en vie réelle
21. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients
22. La sarcopénie associée à un IMC>25kg/m2 est prédictive de toxicité sévère précoce sous anti-PD1 chez les patients atteints de mélanome
23. Une histoire naturelle lente est associée à un meilleur taux de réponse aux anti-PD1 dans le mélanome
24. Sarcopenia associated with a body mass index (BMI) > 25 kg/m2 predicts severe acute toxicity of nivolumab and pembrolizumab in melanoma patients
25. Estimation of glomerular filtration rate in patients with abnormal body composition and relation with carboplatin toxicity
26. Identification of patients at risk for severe toxicity under PD1 inhibitors: role of sarcopenic overweight
27. Slow natural history predicts higher response rate to nivolumab and pembrolizumab in advanced melanoma patients
28. Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue
29. Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker
30. Hypermétabolisme, cachexie et toxicité des traitements anti-tumoraux : étude prospective chez 277 patients atteints de cancer
31. L’intervalle entre le diagnostic et la cystectomie totale n’a pas d’impact sur le devenir oncologique des patients traités par chimiothérapie néoadjuvante
32. 371 Potential benefit of pharmacokinetically-guided dosing strategy for the decision making in cancer patients treated with sunitinib
33. 2547 Low abiraterone plasma concentration fails to induce PSA regression in metastatic castration-resistant prostate cancer patients
34. 3451 Insulin-resistance in sarcoma patients: analysis of a prospective cohort
35. 1319 A prevalence study of drug-drug interactions in metastatic prostate cancer patients receiving abiraterone
36. Sarcopenia and Acute Severe Toxicity in Sarcoma Patients Treated with Doxorubicin-Based Chemotherapy
37. Ocular Adverse Effects (OAES) of Molecularly Targeted Agents (MTAS) Approved in Oncology: A Systematic Review
38. Importante plasmocytose sanguine et médullaire réactionnelle à un lymphome angioimmunoblastique
39. Panniculite rétropéritonéale
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.